作者
Yago Nieto,Jeremy Ramdial,Benigno C. Valdez,Peter F. Thall,Roland L. Bassett,M. J. Barnett,Samer A. Srour,Chitra Hosing,Amin M. Alousi,Muzaffar H. Qazilbash,Uday Popat,Alison Gulbis,Terri Lynn Shigle,Sairah Ahmed,Manuel Matamoros Pacheco,Richard E. Champlin,Elizabeth J. Shpall,Börje S. Andersson
摘要
Abstract Purpose: More active high-dose chemotherapy (HDC) regimens are needed for autologous stem cell transplantation (ASCT) for refractory lymphomas. Seeking HDC enhancement with a PARP inhibitor, we observed marked synergy between olaparib and vorinostat/gemcitabine/busulfan/melphalan (GemBuMel) against lymphoma cell lines, mediated by the inhibition of DNA damage repair. Our preclinical work led us to clinically study olaparib/vorinostat/GemBuMel with ASCT. Patients and Methods: Patients ages 15 to 65 years with refractory lymphoma and adequate end-organ function were eligible for this phase I trial. The olaparib dosage was escalated from 25 mg orally twice a day on days −11 to −3, plus vorinostat (1,000 mg orally/day, days −10 to −3), gemcitabine (2,475 mg/m2/day i.v., days −8 and −3), busulfan (target AUC 4,000 µmol/L.minute−1/day i.v., days −8 to −5), melphalan (60 mg/m2/day i.v., days −3 and −2), and rituximab (CD20+ tumors; 375 mg/m2, day −10), with ASCT. Results: Fifty patients were enrolled (23 with Hodgkin lymphoma, 18 with diffuse large B-cell lymphoma, and 9 with T-cell non–Hodgkin lymphoma); the median age was 35 years (range, 20–61); patients received a median of three prior lines of therapy (range, 2–7); 17 patients had previously relapsed after chimeric antigen receptor T-cell therapy or other cellular immunotherapies; 23 patients had PET-positive tumors at HDC (9 in progression). An olaparib dosage of 150 mg orally twice a day was identified as the recommended phase II dosage. The main extramedullary toxicity was mucositis. The overall response rate and complete response rate were 100% and 90%, respectively. At the median follow-up of 30 (range, 12–56) months, the event-free survival and overall survival rates were 72% and 82% in all patients and 71% and 88% in patients with prior CAR T-cell failure, respectively. Conclusions: In this first trial combining a PARP inhibitor with HDC, olaparib/vorinostat/GemBuMel was safe and showed promising activity in refractory lymphomas, including post–CAR-T relapses.